Latest Proton pump inhibitors Stories
- Company Also Submits sNDA for NEXIUM Capsules for Risk Reduction of Low-Dose Aspirin-Associated Peptic Ulcer - WILMINGTON, Del., May 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a new drug application (NDA) to the U.S.
In a new study, published in the May issue of Elsevier's Experimental Neurology (www.elsevier.com/locate/yexnr), scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.
The surprising results of a recent study indicate that the decades long medical practice of prescribing heartburn medications to patients with asthma is ineffective.
--Practice Changing Study Calls on Doctors to Stop Prescribing Potent Heartburn Medications to Asthma Patients Without Frequent Symptoms of Gastric Reflux-- WASHINGTON, April 8 /PRNewswire-USNewswire/ -- For nearly 20 years, it was believed that severe asthma symptoms such as coughing, wheezing and breathlessness were triggered in part by acid reflux.
DEERFIELD, Ill., Feb. 23 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that KAPIDEX(TM) (dexlansoprazole) delayed release capsules are now available in pharmacies across the U.S. KAPIDEX, available in 30 mg and 60 mg doses, was recently approved by the U.S.
First proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation DEERFIELD, Ill., and OSAKA, Japan, Jan. 30 /PRNewswire/ -- Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S.
Patients taking the common cardiac drug clopidogrel following a heart attack are at a significantly higher risk of a recurrence if they are also taking widely used acid-lowering medications called proton pump inhibitors, a new study published online in CMAJ has found
PITTSBURGH, Jan. 23 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S.
-Filing also includes age appropriate formulation of 2.5 mg and 5 mg strengths of NEXIUM for Delayed-Release Oral Suspension- WILMINGTON, Del., Dec. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S.
According to a new study, stent patients who take the blood thinner Plavix combined with heartburn drugs may face a greater risk of heart attack.
- totally perplexed and mixed up.